Literature DB >> 13680123

The prevalence of insulin autoantibodies at the onset of Type 1 diabetes is higher in males than females during adolescence.

A J K Williams1, A J Norcross, R J Dix, K M Gillespie, E A M Gale, P J Bingley.   

Abstract

AIMS/HYPOTHESIS: The incidence of Type 1 diabetes shows little sex bias up to age 15 years, but more males are diagnosed in early adult life. Humoral responses to the beta cell antigen insulin could help to reveal the mechanism underlying this difference. We therefore determined the influence of sex on the prevalence of insulin autoantibodies (IAA) at diagnosis.
METHODS: IAA were measured by radiobinding assay in 598 patients with newly diagnosed Type 1 diabetes (aged 10.5, range 0.8-20.7 years, 333 male), and analysed according to age, sex and HLA class II genotype.
RESULTS: Overall, 74% of males and 65% of females had IAA above the 97.5(th) centile of 2860 schoolchildren ( p=0.028). IAA prevalence was similar in males and females under the age of 15 (0-4 yr, 95% vs 88%; 5-9 yr, 76% vs 73%; 10-14 yr, 67% vs 58%), but male excess was seen between 15 and 21 years (66% vs. 32%, p(corr)=0.016). HLA class II genotype was available for 426 patients. IAA prevalence in DR4 homozygous patients was 87%, in DR4 heterozygous patients 72% and in DR4 negative patients 55% ( p<0.001). Multivariate analysis showed independent association of IAA with age ( p<0.001), number of DR4 alleles ( p<0.001) and male sex ( p=0.002). CONCLUSIONS/
INTERPRETATION: The prevalence of IAA in patients with newly diagnosed Type 1 diabetes is higher in males than females between 15 and 21 years of age. The lower prevalence of IAA in adolescent females implies sex-specific modulation of the autoimmune process during puberty.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13680123     DOI: 10.1007/s00125-003-1197-2

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  9 in total

1.  Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers.

Authors:  P J Bingley; E Bonifacio; A J Williams; S Genovese; G F Bottazzo; E A Gale
Journal:  Diabetes       Date:  1997-11       Impact factor: 9.461

2.  Concentration of insulin autoantibodies at onset of type I diabetes. Inverse log-linear correlation with age.

Authors:  P Vardi; A G Ziegler; J H Mathews; S Dib; R J Keller; A T Ricker; J I Wolfsdorf; R D Herskowitz; A Rabizadeh; G S Eisenbarth
Journal:  Diabetes Care       Date:  1988-10       Impact factor: 19.112

3.  HLA class II typing of whole genome amplified mouth swab DNA.

Authors:  K M Gillespie; S J Valovin; J Saunby; K M Hunter; D A Savage; D Middleton; J A Todd; P J Bingley; E A Gale
Journal:  Tissue Antigens       Date:  2000-12

Review 4.  Diabetes and gender.

Authors:  E A Gale; K M Gillespie
Journal:  Diabetologia       Date:  2001-01       Impact factor: 10.122

5.  Specific association of HLA-DR4 with increased prevalence and level of insulin autoantibodies in first-degree relatives of patients with type I diabetes.

Authors:  R Ziegler; C A Alper; Z L Awdeh; L Castano; S J Brink; J S Soeldner; R A Jackson; G S Eisenbarth
Journal:  Diabetes       Date:  1991-06       Impact factor: 9.461

6.  Islet autoantibodies, nationality and gender: a multinational screening study in first-degree relatives of patients with Type I diabetes.

Authors:  A J K Williams; P J Bingley; W P T Moore; E A M Gale
Journal:  Diabetologia       Date:  2002-02       Impact factor: 10.122

7.  Diabetes Antibody Standardization Program: first assay proficiency evaluation.

Authors:  Polly J Bingley; Ezio Bonifacio; Patricia W Mueller
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

8.  Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1*0301-DQB1*0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry.

Authors:  C L Vandewalle; T Decraene; F C Schuit; I H De Leeuw; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

9.  Anti-insulin antibodies in children with type I diabetes mellitus. Genetic regulation of production and presence at diagnosis before insulin replacement.

Authors:  R C McEvoy; M E Witt; F Ginsberg-Fellner; P Rubinstein
Journal:  Diabetes       Date:  1986-06       Impact factor: 9.461

  9 in total
  6 in total

1.  Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes.

Authors:  Bart O Roep; Nanette Solvason; Peter A Gottlieb; Joana R F Abreu; Leonard C Harrison; George S Eisenbarth; Liping Yu; Michael Leviten; William A Hagopian; John B Buse; Matthias von Herrath; Joanne Quan; Robert S King; William H Robinson; Paul J Utz; Hideki Garren; Lawrence Steinman
Journal:  Sci Transl Med       Date:  2013-06-26       Impact factor: 17.956

Review 2.  Distinct clinical and laboratory characteristics of latent autoimmune diabetes in adults in relation to type 1 and type 2 diabetes mellitus.

Authors:  Elena Pipi; Marietta Marketou; Alexandra Tsirogianni
Journal:  World J Diabetes       Date:  2014-08-15

Review 3.  Role of B lymphocytes in the pathogenesis of type 1 diabetes.

Authors:  Rochelle M Hinman; John C Cambier
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

Review 4.  B cells and type 1 diabetes ...in mice and men.

Authors:  Rochelle M Hinman; Mia J Smith; John C Cambier
Journal:  Immunol Lett       Date:  2014-01-25       Impact factor: 3.685

5.  Rising incidence of type 1 diabetes is associated with altered immunophenotype at diagnosis.

Authors:  Anna E Long; Kathleen M Gillespie; Saba Rokni; Polly J Bingley; Alistair J K Williams
Journal:  Diabetes       Date:  2012-02-07       Impact factor: 9.461

6.  Latent autoimmune diabetes in adults in a population-based cohort of Polish patients with newly diagnosed diabetes mellitus.

Authors:  Barbara Szepietowska; Anna Głębocka; Urszula Puch; Maria Górska; Małgorzata Szelachowska
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.